Salarius Pharmaceuticals, Inc.

Clinical-stage biopharma developing targeted protein therapies for cancer and viral diseases.

SLRX | NDAQ

Overview

Corporate Details

ISIN(s):: US79400X4043 (+1 more)
LEI:
Country:: United States of America
Address:: 2450 HOLCOMBE BLVD, 77021 HOUSTON
Website:: https://salariuspharma.com/
Sector:: Mining and quarrying
Industry:: Mining of non-ferrous metal ores

Description

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for patients with cancer and other diseases with high unmet medical needs. The company's technology aims to correct the dysregulated gene expression that drives disease progression. Its pipeline is built on two primary drug classes: targeted protein inhibitors (TPIs) and targeted protein degraders (TPDs). The lead TPI candidate, seclidemstat (SP-2577), is in Phase 1/2 clinical trials for solid and hematologic cancers like leukemias and lymphomas. The company's TPD candidate, SP-3164, is in IND-enabling studies. Following a merger with Decoy Therapeutics, Salarius is also advancing peptide therapeutics for cancer and respiratory viruses.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Salarius Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Salarius Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Salarius Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
PhoenixBio Co.,Ltd. CRO providing humanized liver mouse models and testing services for preclinical drug development.	Japan	6190
P&K Skin Research Center Co.,Ltd. Clinical research for dermatological testing in cosmetics, pharma, and health food sectors.	South Korea	347740
Plantarc Bio Ltd. Developing high-yield, resilient crops via gene discovery for global seed companies.	Israel	PLNT
Polymetal International plc A top global gold and silver producer with mining and exploration operations in Kazakhstan.	Kazakhstan	POLY
Poxel Develops drugs for metabolic diseases, including NASH, rare diseases, and an approved diabetes drug.	France	POXEL
PRAP Japan,Inc. A PR & communications firm building brand reputation for corporate clients in diverse industries.	Japan	2449
Predictive Oncology Inc. AI platform uses a vast tumor biobank to predict drug response and accelerate oncology discovery.	United States of America	POAI
Prime Medicine, Inc. Developing 'search and replace' gene editing therapies to treat genetic disorders.	United States of America	PRME
ProPhase Labs, Inc. Genomics, diagnostics, contract manufacturing, and OTC health & wellness solutions provider.	United States of America	PRPH
PROTHENA CORP PUBLIC LTD CO Advancing antibody-based therapies for neurodegenerative and rare amyloid diseases.	United States of America	PRTA